Elsa Pennese

Pescara, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

Journal: British journal of haematology

Published: May 16, 2026

CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy.

CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy.

Journal: Bone marrow transplantation

Published: April 10, 2026

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

Journal: HemaSphere

Published: April 02, 2026

Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.

Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy.

Journal: Leukemia & lymphoma

Published: January 29, 2026

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Journal: Cancers

Published: January 08, 2026

A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma.

A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma.

Journal: American journal of hematology

Published: December 19, 2025

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

Journal: British journal of haematology

Published: November 22, 2025

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Journal: Hematological oncology

Published: October 18, 2025

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort.

Journal: Blood advances

Published: October 15, 2025

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Journal: Blood advances

Published: October 15, 2025

Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes.

Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes.

Journal: British journal of haematology

Published: June 11, 2025

The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study.

The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE-FIRST study.

Journal: HemaSphere

Published: May 13, 2025

Showing 1-12 of 38

Last Updated: 09/26/2026